[Use of rheogluman in the acute period of myocardial infarction].
The efficacy of rheogluman was evaluated in 55 patients with acute myocardial infarction. ECG mapping recordings in 35 leads showed that an earlier positive dynamics in sigma ST, sigma Q, and sigma R was significantly observed in patients treated with rheogluman than in untreated patients. These data indirectly indicated a reduction in the ++peri-infarct zone in the acute period of myocardial infarction. The serum concentrations of lysosomal enzymes (creatine phosphokinase, lactate dehydrogenase, aspartate aminotransferase, alanine amino-transferase) became normal earlier in the rheogluman-treated patients than in the controls. This fact may be regarded as a protective effect of the drug on the formation of a necrotic focus.
Kurbanov
Ia Z
IaZ
Mamedov
Ia D
IaD
Garaev
Sh G
ShG
Kerimova
D N
DN
D000328:Adult; D000368:Aged; D003911:Dextrans / Q000008:administration & dosage*; D004338:Drug Combinations; D015716:Electrocardiography, Ambulatory; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008353:Mannitol / Q000008:administration & dosage*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy*; D010952:Plasma Substitutes / Q000008:administration & dosage*; D012965:Sodium Chloride / Q000008:administration & dosage; D012996:Solutions
D003911:Dextrans; D004338:Drug Combinations; D010952:Plasma Substitutes; D012996:Solutions; C024634:rheogluman; D008353:Mannitol; D012965:Sodium Chloride